ABSTRACT: Bacterial DNA gyrase and topoisomerase IV control the topological state of DNA during replication and are validated targets for antibacterial drug discovery. Starting from our recently reported 4,5,6,7-tetrahydrobenzo[1,2-d]thiazolebased DNA gyrase B inhibitors, we replaced their central core with benzothiazole-2,6-diamine scaffold and interchanged substituents in positions 2 and 6. This resulted in equipotent nanomolar inhibitors of DNA gyrase from Escherichia coli displaying improved inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV from both bacteria. Compound 27 was the most balanced inhibitor of DNA gyrase and topoisomerase IV from both E. coli and S. aureus. The crystal structure of the 2-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzothiazol-6-yl)amino)-2-oxoacetic acid (24) in complex with E. coli DNA gyrase B revealed the binding mode of the inhibitor in the ATP-binding pocket. Only some compounds possessed weak antibacterial activity against Grampositive bacteria. These results provide a basis for structure-based optimization toward dual DNA gyrase and topoisomerase IV inhibitors with antibacterial activity.
■ INTRODUCTION
In the middle of the 20th century, antibiotics were considered to be a powerful discovery that made infectious diseases a problem of the past. Today, it is clear that some of the antibacterial compounds discovered during the past century were only a short-term solution for the treatment of infectious diseases because bacterial resistance to these drugs is increasing and treatments are becoming less effective. 1, 2 Although the discovery of antibiotics is a very important achievement for mankind, the greatest challenges in antibacterial research are yet to come. There is a need for new antibacterial compounds that have new mechanisms of action with activity against resistant bacterial strains, and the search for new antibacterial agents remains a significant challenge for the future.
Bacterial DNA gyrase is a topoisomerase type II enzyme that has attracted attention since its discovery in 1976, when it was first isolated from Escherichia coli 3 and identified as a target of the already known aminocoumarin class of antibacterial compounds. In the 1990s, when the crystal structure of the N-terminal fragment of DNA gyrase had already been solved, 4 topoisomerase IV, a bacterial enzyme with a similar structure, function, and inhibitor susceptibility to DNA gyrase, was identified. 5, 6 DNA gyrase and topoisomerase IV catalyze changes in DNA topology by breaking and rejoining double stranded DNA. In particular, DNA gyrase introduces negative supercoils in DNA in front of the replication fork, while topoisomerase IV is important for decatenation during DNA replication. Thus, both enzymes are involved in very important processes during DNA replication and are essential for cell viability. Both enzymes are ATP-fueled heterotetrameric proteins; DNA gyrase is composed of two A subunits (GyrA) and two B subunits (GyrB), whereas topoisomerase IV consists of two C subunits (ParC) and two E subunits (ParE), which are homologous to GyrA and GyrB, respectively. 7 The GyrA and ParC subunits are involved in DNA transit, while the GyrB and ParE subunits contain an ATP-binding domain. 8 Type II topoisomerase is also found in eukaryotic cells, but unlike the prokaryotic enzymes, eukaryotic topoisomerase II is homodimeric. This difference in structure makes selective targeting of prokaryotic topoisomerase II possible. 7 The similarities in the structure of DNA gyrase and topoisomerase IV offer an exceptional opportunity for the dual targeting of these enzymes by new antibacterial compounds, thereby reducing the probability of bacteria to develop targetbased resistance against them. 9 Thus, the selectivity of targeting prokaryotic topoisomerase II, the potential of dual targeting, and the well-known structure of these enzymes make both DNA gyrase and topoisomerase IV attractive targets in the challenging search for new antibacterial compounds. 9−17 DNA gyrase and topoisomerase IV have been recognized as targets of aminocoumarin and quinolone classes of antibacterial compounds. However, these two classes of inhibitors target different parts of the enzymes. Well known and widely used quinolones target GyrA and ParC subunits, while aminocoumarin class inhibitors target GyrB and ParE subunits. Novobiocin (Figure 1 ), a natural product aminocoumarin class inhibitor of DNA gyrase and topoisomerase IV discovered in the mid-1950s, targets ATP-binding sites at the GyrB and ParE subunits. It is the only GyrB inhibitor to be used in clinical practice, but despite its good pharmacokinetic profile, it was withdrawn from the market primarily due to its toxicity and also due to the high rate of resistance development. Coumermycin A1 and clorobiocin ( Figure 1 ) are two other aminocoumarin natural products that showed good inhibitory activities against DNA gyrase B, but they never reached the market because of their undesirable toxicity profiles. Numerous studies toward the development of improved novobiocin analogues were unsuccessful mainly because of their undesirable pharmacokinetic profile and lack of inhibitory or microbiological activity. Thus, novobiocin is still the only GyrB inhibitor that was used clinically and also the only GyrB inhibitor that has progressed beyond phase I clinical trials. 18 Determination of the crystal structure of DNA gyrase B in complex with adenylyl 5′-(β,γ-imido)triphosphate (ADPNP) in 1991 and later with other known inhibitors of DNA gyrase B 18−20 provided significant information about the most important inhibitor interactions in the protein ATP-binding site. This information created a solid basis for the structurebased design of inhibitors over the years and led to discovery of several new scaffolds that had good potential for inhibition of DNA gyrase and topoisomerase IV. Over the years, using scaffold hopping approaches 21 and exploiting opportunities offered to medicinal chemistry by aromatic heterocycles, 22 benzimidazole ureas, 23 bithiazoles, 24 thiazolopyridines, 25 pyrrolopyrimidines, 26 imidazopyridines, 27 benzothiazoles 28, 29 (Figure 2) , and other structural types 18 have been studied as dual inhibitors of GyrB and ParE subunits of bacterial gyrase and topoisomerase IV. 
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Article ■ RESULTS AND DISCUSSION Design. Our research group has recently reported the discovery of novel structural classes of DNA gyrase inhibitors based on 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole 30 and Nphenyl-4,5-dibromopyrrolamide 31 scaffolds inspired by the marine natural product oroidin ( Figure 3 ). We obtained the crystal structure of 02 in complex with E. coli GyrB and demonstrated that the 4,5-dibromo-1H-pyrrole-2-carboxamide moiety of 01 and 02 bound to the ATP binding site of GyrB participates in a hydrogen bond with the Asp73 carboxylate group and a conserved water molecule, whereas the terminal carboxylic acid moiety is involved in interactions with Arg76 and/or Arg136. 30, 31 On the basis of the crystal structure of the E. coli GyrB−02 complex and potent inhibition of E. coli DNA gyrase by 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole class inhibitors in conjunction with their weaker inhibition of Staphylococcus aureus DNA gyrase and E. coli and S. aureus topoisomerase IV, we examined the effects of different structural modifications of the parent compound 01 on the inhibition of both enzymes. First, the 4,5,6,7-tetrahydrobenzo-[1,2-d]thiazole moiety was replaced by a planar aromatic benzothiazole scaffold to enable additional cation−π interaction of the benzene ring with Arg76 within the Glu50-Arg76 salt bridge, which is not present in the 4,5,6,7-tetrahydrobenzo[1,2-d] series and was shown to be important for the strong inhibition of DNA gyrase B. 18 The benzothiazole scaffold additionally made possible the substitution pattern which proved to be successful in the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole series. 30 Second, because our docking experiments ( Figure 4 ) suggested similar binding modes of compounds incorporating the pyrrole-2-carboxamido moiety at positions 6 (series A) and 2 (series B) of the central heterocyclic core, series B analogues of the parent compound 01 were prepared in addition to series A compounds. Third, the dibromopyrrole moiety was replaced by a smaller dichloropyrrole moiety to possibly improve multiple inhibition against S. aureus DNA gyrase and E. coli and S. aureus topoisomerase IV because these three enzymes possess a smaller hydrophobic pocket compared to that of E. coli DNA gyrase. 30 Finally, the effect of the length of the ester or carboxylic acid moieties on the multiple inhibition of DNA gyrase and topoisomerase IV was evaluated. As demonstrated below, this resulted in an improved inhibitor series that possesses inhibitory activity against topoisomerase IV from both bacterial strains. The crystal structure of series B compound 24 in complex with E. coli DNA gyrase B revealed the binding mode of the studied benzothiazole class of , rt, 24 h; (c) (i) 4,5-dibromo-1H-pyrrole-2-carboxylic acid (for 8, 9 and 10) or 4,5-dichloro-1H-pyrrole-2-carboxylic acid (for 11 and 12), oxalyl chloride, DCM, rt, 15 h, then (ii) 5 (for 8 and 11), 6 (for 9 and 12), or 7 (for 10), pyridine, DCM, rt, 2 h; (d) 1 M NaOH, MeOH, rt, 24 h.
Article compounds, thus providing a solid basis for structure-based design and optimization of this promising class of ATP-binding site targeting DNA gyrase B inhibitors.
Chemistry. The synthesis of the series A compounds with the pyrrole-2-carboxamido group attached at position 6 of the benzothiazole-2,6-diamine scaffold is presented in Scheme 1. Acylation of 1 with appropriate acyl chloride (ethyl oxalyl chloride, methyl malonyl chloride, or methyl succinyl, chloride) in the presence of triethylamine in 1,4-dioxane at room temperature afforded compounds 2, 3, and 4. The reduction of the nitro group of 2−4 using catalytic hydrogenation in the presence of 10% Pd/C in methanol or ethanol yielded amines 5, 6, and 7. These were acylated with freshly prepared 4,5-dibromo-1H-pyrrole-2-carbonyl chloride or 4,5-dichloro-1H-pyrrole-2-carbonyl chloride in the presence of pyridine in dichloromethane to obtain esters 8−12. Compounds 8 and 10 were hydrolyzed with 1 M sodium hydroxide in methanol to produce carboxylic acids 13 and 14. All attempts to hydrolyze malonic acid derivatives 9 and 12 were unsuccessful due to decarboxylation that, surprisingly, did not compromise the hydrolysis of the series B esters 18−23 (Scheme 2) and related 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole analogs. 30 Synthesis of compounds from series B started from the commercially available 6-nitrobenzothiazol-2-amine (1), which was catalytically hydrogenated to benzothiazole-2,6-diamine (15) in a Parr hydrogenator at 2.1 bar pressure, using ethanol as a solvent and 10% Pd/C as a catalyst. The diamine 15 was further coupled with 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-yl)ethan-1-one or 2,2,2-trichloro-1-(4,5-dichloro-1H-pyrrol-2-yl)ethan-1-one in the presence of Na 2 CO 3 as a base in N,Ndimethylformamide at 80°C to obtain pyrrolamides 16 and 17. Acylation of 16 and 17 with ethyl oxalyl chloride, methyl malonyl chloride, or methyl succinyl chloride at room temperature in the presence of triethylamine in 1,4-dioxane afforded esters 18−23, which were hydrolyzed to carboxylic acids 24−29 upon treatment with 1 M sodium hydroxide in methanol (Scheme 2).
In Vitro Inhibition of DNA Gyrase and Topoisomerase IV. Synthesized benzothiazole derivatives were evaluated for their inhibitory activity against DNA gyrase and topoisomerase 
Article IV from both E. coli and S. aureus in supercoiling and decatenation assays, respectively. The inhibitory activities of the tested compounds are presented in Tables 1 and 2 as IC 50 values. Inhibitory Activities against DNA Gyrase. In the series A compounds, in which the 4,5-dichloro-or 4,5-dibromopyrrolamido moiety is attached at the position 6 of the benzothiazole ring, the most favorable acyl substituent at position 2 proved to be the oxalyl group, both in the ester and in the free carboxylic acid form as demonstrated by the most potent inhibitor 13 (IC 50 = 38 nM) of E. coli DNA gyrase among compounds in the series A ( Table 1 ). The dichloro ester analogues 11 and 12 displayed weaker inhibition of E. coli DNA gyrase than the corresponding dibromo analogues, so the respective carboxylic acids were not prepared. The inhibitory potency of dibromo ethyl oxalate 8 equaled that of the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole analogue (IC 50 = 100 nM), while the methylmalonate and methylsuccinate esters 9 and 10 were found to be 2-fold and 9-fold weaker inhibitors of E. coli DNA gyrase than the corresponding 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole analogues. 30 The carboxylic acid inhibitors 13 (IC 50 = 38 nM) and 14 (IC 50 = 57 nM) were equipotent with the corresponding 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole analogues (oxalyl analogue, IC 50 = 58 nM; succinyl analogue, IC 50 = 49 nM). 30 Compounds from series A did not display a substantial S. aureus DNA gyrase inhibition (Table 1) .
From the inhibitory activities of series B compounds 16 and 17, shown in Table 2 , it can be concluded that the 4,5-dibromo-1H-pyrrolamide moiety attached at position 2 on the benzothiazole ring contributes to the affinity for the ATPbinding site of E. coli DNA GyrB more than the 4,5-dichloro-1H-pyrrolamide moiety attached at the same position. This trend was also observed for the activities of other compounds from series B containing the 4,5-dibromo-1H-pyrrolamide moiety (cf. 18 vs 21 and 20 vs 23, 24 vs 27 and 26 vs 29), with the exception of the malonyl pairs 19 and 22 and 25 and 28, in which a trend of stronger inhibition by the 4,5-dichloro-1H-pyrrolamide compounds was observed. On the contrary, the differences between the dibromopyrrole and dichloropyrrole compounds were not straightforward for inhibition of DNA gyrase from S. aureus. Ethyl oxalyl, methyl malonyl, and methyl succinyl moieties attached at position 6 of the benzothiazole ring improved the inhibitory activities of the dichloropyrrole compounds 21−23 but not of the dibromopyrrole compounds 18−20 against E. coli DNA gyrase, with the methyl malonyl derivative 22 (IC 50 = 0.22 μM) being the most potent inhibitor in this ester series. In the carboxylic acid series (compounds 24−29) the measured IC 50 values for inhibition of DNA gyrase from E. coli were all in the nanomolar range, due to the contribution of the carboxylate group interaction with Arg136. The most potent inhibitors in the dibromopyrrole carboxylic acid series were succinyl and oxalyl derivatives 26 (IC 50 = 33 nM) and 24 (IC 50 = 58 nM), while for the dichloropyrrole compounds the most potent inhibitor was oxalyl compound 27 with an IC 50 value of 87 nM. The affinity of compound 24 for DNA gyrase B from E. coli was further confirmed by surface plasmon resonance (SPR) (for experimental details see ref 29 ) with a K d of 0.23 μM. The inhibition of S. aureus DNA gyrase was observed only for the dibromopyrrole carboxylic acid 25 (IC 50 = 5.6 μM) and dichloropyrrole carboxylic acids 27−29, with IC 50 values in the range of 0.51−94 μM. Generally, all of the compounds from series B displayed weaker inhibition of S. aureus DNA gyrase compared to E. coli gyrase. It is worth noting the low micromolar activity of malonyl compounds 25 in the dibromo series (IC 50 = 5.6 μM) and 28 in the dichloro series (IC 50 = 8.5 μM) against S. aureus gyrase. The nanomolar activity of the dichloro oxalyl derivative 27 (IC 50 = 0.51 μM) in comparison to dibromo analogue 24 (IC 50 > 100 μM), as well as to malonyl analogue 28 (IC 50 = 8.5 μM) and succinyl analogue 29 (IC 50 = 94 μM), is also noteworthy, indicating that the carboxylic acid moiety and small changes in the length of the acyl moiety (cf. 24 vs 25, 27 vs 28) are important for the binding of series B compounds to the ATP-binding site of S. aureus DNA gyrase. Journal of Medicinal Chemistry
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In addition, substitution in the pyrrole ring (cf. 24 vs 27) is important for the orientation of the whole molecule in the binding pocket of S. aureus DNA gyrase. The main difference between the compounds from the series B (pyrrole-2-carboxamido group at position 2) and series A (pyrrole-2-carboxamido group at position 6) is that the compounds in series B exhibited better inhibitory activity against S. aureus DNA gyrase, while their inhibitory activity against E. coli DNA gyrase remained in the nanomolar range. Inhibitory Activities against Topoisomerase IV. Generally, the inhibitory potencies of most of the series B compounds against topoisomerase IV were lower than those against DNA gyrase for the E. coli enzymes, but for the S. aureus enzymes, the IC 50 values for the inhibition of both enzymes were more comparable (Tables 1 and 2 ). Inhibition of topoisomerase IV by most of the active compounds (13, 14, and 24−29) was better than or comparable to that of novobiocin (IC 50 (E. coli) = 11 μM; IC 50 (S. aureus) = 27 μM). The esters 8−12 and 18−23 did not show any promising activity, which indicates that a carboxylic acid moiety is required for the binding of the compounds in the ATP-binding site of topoisomerase IV. All of the final carboxylic acids (13, 14, and 24−29) from both series A and B exhibited low micromolar activities against topoisomerase IV from both E. coli and S. aureus.
Compounds 25, 27, and 28 were found to be especially interesting for further studies because they showed promising inhibitory activities against all four tested enzymes. In particular, 4,5-dichloropyrrole-based benzothiazole inhibitor 27 exhibited well-balanced multiple inhibition of all four enzymes in the nanomolar and low micromolar range (0.087− 1.8 μM).
Antibacterial Activity. All of the compounds from series A and series B were tested against two Gram-positive (Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC 29212) and two Gram-negative (Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853) bacterial strains. In general, the compounds did not show significant antibacterial activities against either Gram-positive or Gram-negative bacteria. The only notable activities were observed against Gram-positive E. faecalis for compounds 25 and 11 which showed 59% and 47% inhibition of the growth of E. faecalis at a 50 μM concentration after 24 h incubation, respectively. None of the final compounds showed significant antibacterial activity against the tested Gram-negative bacteria. Because a possible reason for the absence of the antibacterial activity of compounds against Gram-negative bacteria could be their affinity for efflux pumps, we tested the compounds 17−19, 21− 25, 27, and 29 in ΔtolC E. coli, an efflux deficient strain derived from wild-type E. coli ECM1194 that lacks a functional tolC gene that encodes the essential outer membrane component of the multicomponent efflux pump (for experimental details see ref 30) . We found that compound 25 exhibited more potent antibacterial activity (MIC < 16 μg/mL) in ΔtolC, than in the wild type E. coli strain that contained efflux pump (MIC > 256 μg/mL). These results may explain the weak antibacterial activity of 25 and similar compounds against both Gramnegative bacterial strains tested, with only 12% inhibition of the growth of E. coli and 11% inhibition of the growth of P. aeruginosa after a 24 h incubation.
X-ray Crystallography and Molecular Modeling. A detailed binding mode of the series B inhibitor 24 in the ATPbinding site of the 43 kDa N-terminal fragment of the E. coli DNA gyrase B (residues Gly15 to Thr392) was revealed from the X-ray cocrystal structure, which was solved to a resolution of 2.83 Å (PDB code 5L3J). The electron density for most of the ligand is well-defined but is missing for the terminal carboxylate group ( Figure 5 ), which can probably be attributed to its flexibility in the binding site. Similar situation was observed in the cocrystal structure of E. coli DNA gyrase in complex with N-phenyl-4,5-dibromopyrrolamide inhibitor, where the mobility of the inhibitor in the binding site was also shown through molecular dynamics simulation. 31 In contrast, the high resolution crystal structure of bithiazole inhibitor in complex with E. coli DNA gyrase (PDB entry 4DUH) revealed a hydrogen bond between the inhibitor and Gly101 carbonyl oxygen, which stabilized the Gly97-Ser108 flexible loop, decreased ligand flexibility, and enhanced chances for obtaining a high resolution structure. 24 Lack of the structural feature in this series of the benzothiazole inhibitors, enabling hydrogen bonding with amino residues of the Gly97-Ser108 flexible loop, thus probably also contributed to the higher mobility of ligand in the binding site and consequently to the lower crystal structure resolution of E. coli DNA gyrase− 24 complex.
The orientation and conformation of the terminal carboxylate group of 24 were hence modeled in two different ways 
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Article ( Figure 5 ; model 1, model 2), and it is located in the vicinity of Arg76 and Arg136, which are usually in contact with DNA gyrase B inhibitors. 9, 18 However, the electron density for the Arg76 side chain is missing in the experimental data and no hydrogen bonds can be predicted. The 4,5-dibromopyrrolamide moiety of 24 is bound to the adenine binding pocket, where a hydrogen bond between the pyrrole NH group and Asp73 side chain is formed. However, due to the X-ray structure resolution of 2.83 Å, only a few water molecules were modeled based on the electron density, and the conserved water molecule was not observed in the structure. Therefore, a hydrogen bond between the inhibitor carbonyl group and Asp73 side chain bridged by this water molecule could not be observed. The 4,5-dibromopyrrole moiety forms additional hydrophobic contacts with Val43, Asn46, Val71, Val120, Thr165, and Val167, while the benzothiazole scaffold forms hydrophobic interactions with Glu50, Gly77, Ile78, and Pro79.
Possible binding modes of DNA gyrase inhibitors of the benzothiazole-2,6-diamine series A and B were also studied following our recently described docking protocol, 30 using LeadIT and the high resolution structure of E. coli DNA gyrase in complex with a bithiazole inhibitor. 24 Comparison of the predicted ( Figure 4a ) and experimental binding mode ( Figure  5a ) of 24 in the E. coli DNA gyrase ATP-binding site shows similar conformation of the ligand, while its position is slightly different. The docking predicts the formation of hydrogen bonds between the terminal oxalate moiety and Arg76 and Arg136 side chains that could not be observed in the X-ray structure ( Figure 5 ). Such hydrogen bonds are predicted for all oxalic (8, 11, 13, 18, 21, 24 , and 27), malonic (9, 12, 19, 22, 25 , and 28) and succinic acid (10, 14, 20, 23, 26 , and 29) derivatives in both series A and series B. As an example, the predicted binding mode of series A compound 13, which has the opposite substitution as 24, is presented in Figure 4b .
■ CONCLUSION
In summary, replacement of the central core of 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-based DNA gyrase B inhibitors 29 with a planar benzothiazole-2,6-diamine scaffold and moving the 4,5-dihalopyrrole-2-carbonyl group from N-6 to N-2 of the central core resulted in two series of nanomolar inhibitors. These compounds were nearly equipotent with the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole compounds as inhibitors of E. coli DNA gyrase but displayed improved inhibition of S. aureus DNA gyrase and topoisomerase IV from both bacteria. A crystal structure of 2-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzothiazol-6-yl)amino)-2-oxoacetic acid (24) in complex with E. coli DNA gyrase B solved to a resolution of 2.83 Å revealed the binding mode of the inhibitor in the ATPbinding pocket of the enzyme. In general, no significant antibacterial activity against both Gram-negative and Grampositive bacteria was observed, most likely due to efflux of inhibitors. Some of the compounds possessed only weak antibacterial activity against Gram-positive E. faecalis. The results of this study provide a good starting point for structurebased design of improved ATP-competitive DNA gyrase and topoisomerase IV inhibitors with antibacterial activity. In this respect, compounds 25, 27, and 28 are especially interesting for further studies because they showed promising well balanced multiple inhibiton in the nanomolar/low micromolar range against DNA gyrase and topoisomerase IV in both E. coli and S. aureus.
■ EXPERIMENTAL SECTION
Chemistry. The chemicals obtained from Sigma-Aldrich (St. Louis, MO, USA), Acros Organics (Geel, Belgium), and Appollo Scientific (Stockport, U.K.) were used without further purification unless otherwise stated. Analytical TLC was performed on 0.25 mm silica gel Merck 60 F 254 plates, using visualization with UV light and spray reagents. Column chromatography was carried out on Merck silica gel 60 (particle size 240−400 mesh). Melting points were determined on a Reichert hot stage microscope and are uncorrected.
1 H NMR and 13 C spectra were recorded at 400 and 100 MHz, respectively, on a Bruker AVANCE III spectrometer in DMSO-d 6 or CDCl 3 solution with TMS as an internal standard at room temperature. IR spectra were obtained using a Thermo Nicolet Nexus 470 ESP FT-IR spectrometer. Mass spectra were recorded on a VG Analytical Autospec Q mass spectrometer. HPLC analyses were run on an Agilent Technologies 1100 instrument (Agilent Technologies, Santa Clara, CA, USA) with a G1365B UV−vis detector, a G1316A thermostat, and a G1313A autosampler using a Phenomenex Luna 5 μm C18 column (4.6 mm × 150 mm or 4.6 mm × 250 mm, Phenomenex, Torrance, CA, USA) and a flow rate of 1.0 mL/min. The eluent consisted of 0.1% trifluoroacetic acid in water (A) and methanol (B); gradient, from 90% A to 10% A in 20 min, then 5 min 10% A; flow rate 1.0 mL/min; injection volume, 10 μL. All tested compounds had a purity of at least 95% by HPLC and passed the PAINS filter (see below).
General Procedure A. Synthesis of Compound 2, 3, and 4. 6-Nitrobenzothiazol-2-amine (1) (1.95 g, 10.0 mmol) was dissolved in 1,4-dioxane (100 mL). Triethylamine (2.09 mL, 15.0 mmol) was added, and the mixture was cooled down to 0°C. Ethyl oxalyl chloride (1.68 mL, 15.0 mmol), methyl malonyl chloride (1.61 mL, 15.0 mmol), or methyl succinyl chloride (1.85 mL, 15.0 mmol) was added dropwise to the mixture, and the reaction mixture was stirred for an additional 3 h at room temperature, whereupon saturated NaHCO 3 solution was added to quench the reaction. The reaction mixture was concentrated in vacuo, dissolved in ethyl acetate, and the solution was washed with 3 × 10 mL of saturated NaHCO 3 , 3 × 10 mL of 10% citric acid, 3 × 10 mL of water, and 3 × 10 mL of brine. If the product precipitated between the ethyl acetate and water phase, it was collected by filtration. The ethyl acetate phase was dried over sodium sulfate and concentrated. The combined crude products were recrystallized from ethyl acetate. To a solution of 4,5-dibromo-1H-pyrrole-2-carboxylic acid (for 8, 9, and 10) (0.250 g, 0.930 mmol) or 4,5-dichloro-1H-pyrrole-2-carboxylic acid (for 11 and 12) (0.167 g, 0.930 mmol) in anhydrous dichloromethane (20 mL), oxalyl chloride (0.46 mL of 2 M solution in methylene chloride, 0.93 mmol) was added, and the reaction mixture was stirred for 15 h. The solvent was removed under reduced pressure whereupon dichloromethane (15 mL), pyridine (5 mL), appropriate amine (1.00 mmol) were added to the residue and stirred for 2 h at room temperature The reaction mixture was concentrated and dissolved in ethyl acetate (50 mL) and the solution washed successively with 1 M HCl (10 mL), NaHCO 3 (10 mL), water (10 mL), and brine (10 mL). The ethyl acetate phase was dried over sodium sulfate and concentrated. The crude products were recrystallized from methanol. General Procedure D. Synthesis of Compounds 13, 14, and 24−29. Hydrolysis of esters 8, 10, and 18−23 (1.00 mmol) was performed with 1 M NaOH (2.00 mL, 2.00 mmol) in methanol (10 mL) at room temperature overnight. After evaporation of the methanol, the reaction mixture was acidified with 1 M HCl to pH 3 and the precipitated carboxylic acids were collected by filtration.
Ethyl 2-((6-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzo-[d]thiazol-2-yl)amino)-2-oxoacetate (8)
2-((6-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzo[d]-thiazol-2-yl)amino)-2-oxoacetic Acid (13 21, 22, 23) and triethylamine (0.10 mL, 0.79 mmol) in 1,4-dioxane (20 mL) cooled to 0°C, ethyl oxalyl chloride (0.089 mL, 0.79 mmol), methyl malonyl chloride (0.084 mL, 0.79 mmol), or methyl succinyl chloride (0.097 mL, 0.79 mmol) was added dropwise, and the reaction mixture was stirred for additional 3 h at room temperature. Saturated NaHCO 3 solution was added to quench the reaction. The mixture was concentrated, dissolved in ethyl acetate (25 mL), and the solution was washed with saturated NaHCO 3 solution (3 × 10 mL), 10% citric acid (3 × 10 mL), water (3 × 10 mL), and brine (3 × 10 mL). If the product precipitated between the ethyl acetate and water phase, it was collected by filtration. The ethyl acetate phase was dried over sodium sulfate and concentrated in vacuo. The crude products were recrystallized from ethyl acetate. 3309,  2988, 2362, 1708, 1657, 1614, 1579, 1538, 1472, 1440, 1384, 1359,  1318, 1297, 1278, 1262, 1214, 1172, 1103, 1057, 996 3364, 1718, 1660,  1612, 1578, 1533, 1470, 1436, 1408, 1382, 1316 6 .5% (w/v) glycerol, 0.0001 g/mL albumin] containing 1.5 U of gyrase from E. coli or S. aureus, 0.75 μg of relaxed pNO1 plasmid, and inhibitor (in 3 μL of 10% DMSO and 0.008% Tween 20 solution). After a 30 min incubation at 37°C the enzymatic reaction was terminated with the addition of the TF buffer [50 mM NaOAc (pH 5.0), 50 mM NaCl, and 50 mM MgCl 2 ] and left for another 30 min at room temperature to allow the formation of biotin− oligonucleotide−plasmid triplex, and then TF buffer was used to wash off the unbound plasmid. 200 μL of SybrGOLD stain (diluted 1000×) in T10 buffer [10 mM Tris-HCl (pH 8.0) and 1 mM EDTA] was added, mixed, and the fluorescence (λ ex = 485 nm; λ em = 535 nm) was measured with BioTek's Synergy H4 microplate reader. Inhibitor concentrations of 100 and 10 μM were used for initial screening. For selected compounds, IC 50 values were determined with seven concentrations of the inhibitors. GraphPad Prism program was used for calculating IC 50 value which represents the concentration of inhibitor where the activity of the enzyme is reduced by 50%. IC 50 values were determined in three independent measurements, and their average value is given as a result. As a positive control novobiocin (Sigma-Aldrich) [IC 50 = 0.17 μM (lit. 0.08 μM) 31, 32 for E. coli gyrase and IC 50 = 0.041 μM (lit. 0.01 μM) 31,32 for S. aureus gyrase] was used. Evaluation of Inhibitory Activities on E. coli and S. aureus Topoisomerase IV. Commercially available assay (Inspiralis) for the determination of IC 50 values was used on streptavidin-coated black 96-well microtiter plates (Thermo Scientific Pierce). Wash buffer [137 mM NaCl, 20 mM Tris-HCl (pH 7.6), 0.01% (w/v) BSA, 0.05% (v/v) Tween 20] was used to rehydrate the plates and then biotinylated oligonucleotide was immobilized on the plates. Wash buffer was used to remove the nonbound oligonucleotide. The assay was carried out with the final volume of 30 μL, using buffer [40 mM HEPES (pH 7.6), 100 mM potassium glutamate, 10 mM magnesium acetate, 10 mM DTT, 1 mM ATP, 0.000 05 g/mL albumin] containing 1.5 U of topoisomerase IV from E. coli or S. aureus, 0.75 μg of supercoiled pNO1 plasmid and inhibitor (in 3 μL of 10% DMSO and 0.008% Tween 20 solution). The mixture was incubated for 30 min at 37°C, then the enzymatic reaction was terminated with the addition of the Crystallography. Protein production, crystallization, preparation of the inhibitor−protein complexes, data collection and processing, and structure modeling and refinement were performed by Proteros Biostructures GmbH, Martinsread, Germany.
Protein Production. The expression of GyrB was performed according to previously established protocols using a suitable previously established construct that allowed production of homogeneous protein in preparative amounts. The protein was purified using affinity and gel filtration chromatography steps that yielded homogeneous protein with a purity better than 95% as judged from Coomassie stained SDS−PAGE.
Crystallization. The purified protein was used in crystallization trials employing both a standard screen (∼1200 different conditions) as well as crystallization conditions identified in literature. Conditions initially obtained have been optimized using standard strategies, systematically varying critical parameters influencing crystallization, such as protein concentration, temperature, drop ratio, and others. These conditions were also refined by systematical variation of pH and precipitant concentrations.
Data Collection and Processing. A cryoprotocol was established using PROTEROS Standard Protocols. Crystals were flash-frozen and measured at the temperature of 100 K. The X-ray diffraction data were collected from crystals of complex of the ligand 24 with GyrB at the Swiss Light Source (Villigen, Switzerland) using cryogenic conditions. The crystals belonged to space group C2. The programs XDS and XSCALE were used for data processing. Tables 3 and 4 summarize the data collection and refinement statistics.
Molecular Modeling. Ligand and Protein Preparation. Threedimensional models of the final compounds were built in ChemBio3D Ultra 13.0. 33 Their geometries were optimized using MMFF94 34 force field, partial atomic charges were added, and energy was minimized until the gradient value was below 0.001 kcal/(mol Å). Further refinement with GAMESS interface in ChemBio3D Ultra 13.0 using the semiempirical PM3 method, QA optimization algorithm, and Gasteiger−Huckel charges for all atoms for 100 steps was performed. 34 Molecular docking of the final molecules was performed using FlexX, 35, 36 as available in LeadIT, 37, 38 running on four octal core AMD Opteron CPU processors, 16 GB RAM, two 750 GB hard drives, under 64-bit Scientific Linux 6.0. Receptor Wizard in LeadIT was used for protein preparation. The binding site was defined as amino acid
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Article residues within a radius of 7 Å around an X-ray crystal structure ligand (PDB entry 4DUH). 22 Correct tautomers and protonation states were assigned, and hydrogen atoms were added to the binding site residues using the Receptor Wizard. The ligand and water molecules, except HOH614, were deleted from the X-ray structure of the complex.
Ligand Docking. The FlexX hybrid algorithm (enthalpy and entropy driven ligand binding), as available in LeadIT, 37, 38 was used to place the "base fragment". The maximum number of solutions per iteration and the maximum number of solutions per fragmentation parameter values were increased to 1000, while other parameters were set at their default values. Docking binding modes of the top five highest scored docking poses per ligand were evaluated, and the highest ranked binding pose was used for graphical representation in PyMOL. 39 Screening against PAINS. To evaluate a library of the synthesized compounds against PAINS, 40 all tested compounds were screened against the PAINS filter using Python script filter_pains.py, downloaded from GitHub (https://github.com/Team-SKI/snippets/blob/ 1d1d0424ba15da08cdc7e18c9a27d55b1a6cb797/Python/filter_pains. py). All compounds passed the PAINS filter. 
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